ACAD
28.26
+0.62
+2.24%
AEMD
2.37
+0.22
+10.23%
APRI
1.1
+0.01
+0.92%
ARNA
16.53
+1.3
+8.54%
ATEC
1.83
+0.04
+2.23%
CNAT
5.6
+0.14
+2.56%
CRXM
0.175
0.00
0.00%
CYTX
1.13
-0.03
-2.59%
DXCM
75.28
+0.34
+0.45%
GNMK
12.51
+0.27
+2.21%
HALO
13.55
-0.44
-3.15%
ILMN
181
+4.64
+2.63%
INNV
0.115
+0.004
+3.604%
INO
8.23
+0.11
+1.35%
ISCO
1.143
-0.008
-0.6522%
ISIS
57.56
0.00
0.00%
LGND
121.37
+2.21
+1.85%
LPTN
2.93
-0.08
-2.66%
MBVX
1.44
0.00
0.00%
MEIP
2.44
+0.1
+4.27%
MNOV
5.28
+0.02
+0.38%
MRTX
3.65
-0.1
-2.67%
MSTX
0.131
-0.007
-5.278%
NBIX
46.77
+1.21
+2.66%
NUVA
78.03
+2.49
+3.30%
ONCS
1.24
+0.06
+5.08%
ONVO
2.69
+0.03
+1.13%
OREX
2.98
-0.1
-3.25%
OTIC
18.35
-0.1
-0.54%
QDEL
27.54
+0.38
+1.40%
RCPT
231.96
0.00
0.00%
RGLS
0.98
-0.07
-6.67%
RMD
77.17
+0.15
+0.19%
SCIE
0
0.00
-16.6667%
SPHS
2.39
-0.02
-0.83%
SRNE
2
-0.05
-2.44%
TROV
1.2
+0.13
+12.68%
VICL
2.6
+0.06
+2.36%
VOLC
18
0.00
0.00%
ZGNX
14.55
+0.25
+1.75%
ACAD
28.26
+0.62
+2.24%
AEMD
2.37
+0.22
+10.23%
APRI
1.1
+0.01
+0.92%
ARNA
16.53
+1.3
+8.54%
ATEC
1.83
+0.04
+2.23%
CNAT
5.6
+0.14
+2.56%
CRXM
0.175
0.00
0.00%
CYTX
1.13
-0.03
-2.59%
DXCM
75.28
+0.34
+0.45%
GNMK
12.51
+0.27
+2.21%
HALO
13.55
-0.44
-3.15%
ILMN
181
+4.64
+2.63%
INNV
0.115
+0.004
+3.604%
INO
8.23
+0.11
+1.35%
ISCO
1.143
-0.008
-0.6522%
ISIS
57.56
0.00
0.00%
LGND
121.37
+2.21
+1.85%
LPTN
2.93
-0.08
-2.66%
MBVX
1.44
0.00
0.00%
MEIP
2.44
+0.1
+4.27%
MNOV
5.28
+0.02
+0.38%
MRTX
3.65
-0.1
-2.67%
MSTX
0.131
-0.007
-5.278%
NBIX
46.77
+1.21
+2.66%
NUVA
78.03
+2.49
+3.30%
ONCS
1.24
+0.06
+5.08%
ONVO
2.69
+0.03
+1.13%
OREX
2.98
-0.1
-3.25%
OTIC
18.35
-0.1
-0.54%
QDEL
27.54
+0.38
+1.40%
RCPT
231.96
0.00
0.00%
RGLS
0.98
-0.07
-6.67%
RMD
77.17
+0.15
+0.19%
SCIE
0
0.00
-16.6667%
SPHS
2.39
-0.02
-0.83%
SRNE
2
-0.05
-2.44%
TROV
1.2
+0.13
+12.68%
VICL
2.6
+0.06
+2.36%
VOLC
18
0.00
0.00%
ZGNX
14.55
+0.25
+1.75%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Arcturus Therapeutics Selected to Present at Biotech Showcase(TM) 2016

January 6, 2016 – 8:30 am

SAN DIEGO, Jan. 6, 2016 /PRNewswire/ — Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, is pleased to announce that the Company has been selected to deliver a corporate presentation at the 8th annual Biotech Showcase™ conference being held January 11-13, 2016 during the JP Morgan Healthcare Conference in San Francisco, CA.  

Joseph E. Payne, President and CEO at Arcturus, will be presenting on Tuesday, January 12, 2016 at 8:15 am PST in the Davidson room of the Parc 55 Hotel. 

Payne stated, “I look forward to providing a corporate overview that includes a summary of key 2015 accomplishments, and updates on our internal preclinical messenger RNA therapeutic programs.” He added, “We continue to see multiple business development opportunities available based on Arcturus’ proprietary UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery technology platforms.”

About Arcturus Therapeutics, Inc.  

Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery. Arcturus’ versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics.  The company owns unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (34 patents and patent applications, issued in the U.S. and other countries).  Arcturus’ proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company’s commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc. (A Johnson and Johnson Company) and Ultragenyx Pharmaceutical, Inc. For more information, visit www.ArcturusRx.com.

About Biotech Showcase™

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.  Now in its eighth year, Biotech Showcase™ 2016 is expected to attract upwards of 2,100 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies. The event is being held January 11-13, 2016 in San Francisco, CA at the Parc 55 Hotel.

Logo – http://photos.prnewswire.com/prnh/20130531/MM24393LOGO

 

SOURCE Arcturus Therapeutics, Inc.

Vigilant Biosciences to Present at the Biotech Showcase(TM) 2016

January 6, 2016 – 7:29 am

FORT LAUDERDALE, Fla., Jan. 6, 2016 /PRNewswire/ — Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that Matthew Kim, Founder, Chairman and CEO of Vigilant Biosciences, Inc., will present at the Biotech Showcase™ 2016, taking place at the Parc 55 in San Francisco, CA, Jan. 11 – 13.

Mr. Kim is scheduled to speak on Wednesday, January 13, 2016, at 11:30 a.m. PST. Mr. Kim will review Vigilant Biosciences’ business strategy and opportunities in regards to its commercialization of the OncAlert™ Oral Cancer System in 2016 as well as other products in the Company’s pipeline.

About the OncAlert Oral Cancer System
The OncAlert Oral Cancer System is the first and only technology that detects specific protein markers associated with oral cancer to aid clinicians in the early detection and intervention of oral cancer. The OncAlert System, comprised of the OncAlert™ Oral Cancer RAPID Test and the OncAlert™ Oral Cancer LAB Test, uses a simple, oral rinse procedure that is easy to administer and non-invasive for the patient. The accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). Vigilant Biosciences’ OncAlertTM LAB Test is CE Marked. The OncAlertTM RAPID Test is currently undergoing the CE Mark registration process and not yet available for sale in any market at this time. The OncAlert Oral Cancer System is not yet available for sale in the U.S.

About Oral Cancer
According to the World Health Organization, there are over 600,000 new cases of head and neck cancer and 300,000 deaths each year worldwide. In the United States, more than 54,000 individuals were diagnosed with head and neck cancers in 2014, with 13,500 deaths from the disease. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Its point-of-care and lab-based products are simple, accurate and cost-effective, empowering healthcare practitioners with an aid in the diagnosis of oral cancer early, and improving lives through earlier intervention. Vigilant Biosciences’ OncAlertTM LAB Test is CE Marked. The OncAlertTM RAPID Test is currently undergoing the CE Mark registration process and not yet available for sale in any market at this time.  For more information, visit www.vigilantbiosciences.com.

Logo – http://photos.prnewswire.com/prnh/20141210/163560LOGO

SOURCE Vigilant Biosciences, Inc.

SutroVax Announces Appointment of Distinguished Conjugate Vaccine Developer Dr. Bruce Forrest to Scientific Advisory Board

January 6, 2016 – 6:55 am

SOUTH SAN FRANCISCO, Calif., Jan. 6, 2016 /PRNewswire/ — SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases, today announced the addition of Dr. Bruce Forrest to the company’s preeminent Scientific Advisory Board, who are collectively responsible for inventing or developing most of today’s blockbuster vaccines. 

Dr. Forrest has over 25 years of global leadership in pharmaceutical development, with extensive specialty expertise in conjugate vaccine development. As a Senior Vice President at Wyeth Pharmaceuticals until 2010, he was responsible for all post-discovery development activities in Wyeth Vaccines Research leading both clinical and pharmaceutical science development contributing to the development of Prevnar 13®. His vaccine experience at Wyeth included responsibility for clinical development of Prevnar and a 9-valent pneumococcal conjugate vaccine and combinations; FluMist®; and clinical responsibility for the EU approval of RotaShield®. At Chiron Corporation, Dr. Forrest was the global clinical team leader for Menjugate® and the adult and adolescent acellular pertussis vaccine program. At Enterovax Limited, he was responsible for the design of the clinical programs for live attenuated typhoid and cholera vaccines.

“Dr. Forrest is renowned for his prominent role in bringing a number of critically important conjugate vaccines to the market including Prevnar®, the most commercially successful vaccine of all time.  His development expertise will be invaluable as we work to harness the Xpress CF platform to deliver the next generation of vaccines to address major and persistent infectious diseases,” said Grant Pickering, Chief Executive Officer of SutroVax.

Conjugate vaccines comprise the largest segment of the vaccine industry, with annual sales approaching $10 billion across multiple licensed indications, including pneumococcus, meningitis, and H flu.  By far the largest of those indications is the pneumococcus market, with annual sales of nearly $6 billion. Despite the successes to date, there are not only a significant number of additional bacterial strains that have yet to be incorporated into current conjugate vaccines, but also many infectious diseases that have yet to be addressed using this potent modality.

“The SutroVax technology is uniquely enabling.  The ability to conjugate site-specifically may well allow the development of broader spectrum vaccines than available today and more potent conjugates to create novel vaccines beyond the reach of other technologies. I look forward to working with the SutroVax team to realize the full potential of this platform,” commented Dr. Forrest.

About Xpress CF

The Xpress CF platform allows for efficient conjugation of antigens to precise positions on carrier proteins via the incorporation of multiple non-natural amino acid (nnAA) substitutions to permit click chemistry attachment. This precise and robust technique results in homogeneous and consistent vaccines that promise to confer important immunological and clinical benefits relative to current conjugate vaccines. Pinpointing the placement of the antigen on the carrier has the potential to improve host immune responses by avoiding the discrete sites on the carrier responsible for T-cell help, which are often impinged by current conjugation methods. Furthermore, the precise optimization of antigen positioning on the carrier protein allows the attachment of multiple antigenic constructs to a single protein carrier, which will facilitate the production of broader spectrum vaccines. These improvements have the potential to deliver best-in-class conjugate vaccines that will have the potential to deliver heightened immunity, broader protection and can be both more easily characterized and consistently produced as a result of our high-yield, streamlined and industrialized production process.

New Website

SutroVax also unveiled a new corporate logo and updated corporate website:  www.sutrovax.com.

About SutroVax

SutroVax is an independent vaccine platform and development company whose mission is to deliver best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases. The company is leveraging its exclusive license to Sutro Biopharma’s Xpress CF platforms to perform cell-free protein synthesis and site-specific conjugation for the field of vaccines. SutroVax closed its Series A round in 2015 and is financed by an international syndicate of experienced, blue-chip venture capital and corporate venture investors. For more information, visit www.sutrovax.com.

Contact:  Grant Pickering
Chief Executive Officer
Email: gpickering@sutrovax.com
www.sutrovax.com

Logo – http://photos.prnewswire.com/prnh/20160105/319546LOGO

 

SOURCE SutroVax

Aridis Pharmaceuticals to Present at Biotech Showcase(TM) 2016

January 6, 2016 – 6:30 am

SAN JOSE, Calif., Jan. 6, 2016 /PRNewswire/ — Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the Company will present at the Biotech Showcase™ 2016, taking place in San Francisco, CA, on January 11–13, 2016.

Vu Truong, Ph.D., Founder and Chief Executive Officer of Aridis Pharmaceuticals, will provide an overview of the Company’s business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Meetings with management may also be scheduled outside of Biotech Showcase by contacting Aridis’ investor relations.

Event:  Biotech Showcase™ 2016
Date: Wednesday, January 13, 2016
Time: 10:45 am (Pacific Time)
Location:  Parc 55 San Francisco

About Aridis Pharmaceuticals, Inc.
Aridis is a privately held biopharmaceutical company applying proprietary monoclonal antibody discovery technology MabIgX® to produce novel infectious disease focused therapies.  Aridis’ product pipeline includes AR-101 (Aerumab®) anti-Pseudomonas aeruginosa LPS human monoclonal antibody; AR-301 (Salvecin®) anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; Aerucin®, a broadly reactive anti-Pseudomonas aeruginosa human monoclonal antibody initially being developed to treat acute pneumonia; Panaecin®, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR- 401 anti-Acinetobacter baumannii human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties.  Such forward-looking statements include statements relating to the therapeutic applications of Aerumab® (AR-101), Salvecin® (AR-301), Aerucin®, Panaecin®, AR-401, AR-201, Aridis’ proprietary formulation and delivery technologies, about Aridis’ strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis’ expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis’ research and clinical studies and its ability to obtain additional financing.  These forward-looking statements represent Aridis’ judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Tiberend Strategic Advisors, Inc. 
Tirth Patel (investors)
tpatel@tiberend.com 
(212) 375-2681

Andrew Mielach (media)
amielach@tiberend.com 
(212) 375-2694

SOURCE Aridis Pharmaceuticals, Inc.

Ena Cratsenburg to Lead Consumer Sector

January 6, 2016 – 6:00 am

SAN FRANCISCO, Jan. 6, 2016 /PRNewswire/ — Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today the appointment of Ena Chan Cratsenburg as Senior Vice President, Consumer Sector.  Ms. Cratsenburg will lead the expansion of Intrexon’s programs to utilize innovative biologically-based applications for the development of products that improve the lives of consumers.

Ms. Cratsenburg brings to Intrexon over two decades experience in leading portfolio development and collaboration strategies for a number of consumer product businesses including cosmetics, flavors and fragrances, food and beverage, and nutritional health markets, as well as alternative fuels. Most recently Ms. Cratsenburg was Senior Vice President, Business Development with Evolva where she was responsible for identifying and evolving commercialization strategies for target businesses as well as successfully leading the development and negotiations of commercial partnerships.  Prior to Evolva, she was Vice President of Business Development for Amyris, where she executed a number of strategic deals around emerging technologies for renewable ingredients.  Ms. Cratsenburg also held business development roles at Pixar Animation Studios and BP plc.  She holds an M.B.A. from the Kellogg Graduate School of Management of Northwestern University and a B.S. in Chemical Engineering from the University of Illinois.

Intrexon’s Chairman and Chief Executive Officer Randal J. Kirk commented, “Ena’s creativity and entrepreneurial spirit along with her proven track record of creating productive partnerships with leading international companies will well serve Intrexon.  Her ability to turn innovative ideas into successful business strategies will help us grow our consumer-focused programs and enter into new markets that are just beginning to appreciate the potential of synthetic biology.”

“I am thrilled to be joining the talented Intrexon team,” Ms. Cratsenburg added. “Intrexon’s portfolio of innovative technologies is transforming the way biologically-based products touch our lives.  I am honored to lead the Consumer Sector and expand that transformation into products that benefit consumers, drive continued growth for the company and further enhance shareholder value. “

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA to create biologically-based products that improve the quality of life and the health of the planet.  The Company’s integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells.  We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com.

Trademarks
Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:
Corporate Contact:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com

Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
investors@intrexon.com

Logo – http://photos.prnewswire.com/prnh/20130919/NY83283LOGO

SOURCE Intrexon Corporation

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LOWR HDV – 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 4) Study at Hannover Medical School in Hannover, Germany

January 6, 2016 – 6:00 am

PALO ALTO, Calif., Jan. 6, 2016 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. today announced the initiation of enrollment and first patient dosed in LOWR HDV – 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 4) at the Hannover Medical School in Hannover, Germany.  LOWR HDV – 4 is an open label, dose titration study designed to evaluate the efficacy and tolerability of lonafarnib combined with ritonavir for a total of 24 weeks in fifteen patients with chronic hepatitis delta.

“We are very pleased to participate in our first Phase 2 study involving lonafarnib in hepatitis delta-infected patients,” said Heiner Wedemeyer, MD, Principal Investigator, Research Group Leader in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School and founding member of the Hepatitis Delta International Network (HDIN).  “We are committed to advancing research and to identifying effective therapeutic options for patients infected with HDV, the most aggressive form of chronic viral hepatitis.”

“Dr. Wedemeyer is a long-time advisor to Eiger BioPharmaceuticals and we are proud to involve Hannover Medical School in our development of lonafarnib for HDV,” said Eduardo Martins, MD, DPhil, Senior Vice President of Liver and Infectious Diseases Drug Development at Eiger BioPharmaceuticals.  “LOWR HDV – 4 is designed to help elucidate the potential benefits of dose titration as well as the antiviral potential of lonafarnib in combination with ritonavir in a longer duration study.”

About Sarasar® (lonafarnib)

Lonafarnib is a well-characterized, late-stage, orally active inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation.  HDV uses this host cell process inside liver cells to complete a key step in its life cycle.  Lonafarnib inhibits the prenylation step of HDV replication inside liver cells and blocks the virus life cycle at the stage of assembly.  Since prenylation is carried out by a host enzyme, this compound may present a higher barrier to development of viral resistance mutations.  Lonafarnib has been dosed in over 50 HDV-infected patients across international academic centers and is in Phase 2 development for HDV.  Lonafarnib has been granted Orphan Drug Designation by the US FDA and European Medicines Agency (EMA), and Fast Track Designation by US FDA.  Lonafarnib is not approved for any indication, and is licensed from Merck Sharp & Dohme Corp. (known as MSD outside of the United States and Canada).

About Hepatitis Delta Virus (HDV)

Hepatitis Delta (or Hepatitis D) is caused by infection with HDV and is considered to be one of the most severe forms of viral hepatitis in humans.  Hepatitis D occurs only as a co-infection in individuals harboring Hepatitis B Virus (HBV).  Hepatitis D leads to more severe liver disease than HBV alone and is associated with accelerated liver fibrosis, liver cancer, and liver failure.  Hepatitis D is a disease with a significant impact on global health, which may affect up to approximately 15 million people worldwide.  The prevalence of HDV varies among different parts of the world.  Globally, HDV infection is reported to be present in approximately 5-6% of chronic Hepatitis B carriers.  The prevalence of HDV in patients infected with chronic HBV is even higher in certain regions, including certain parts of Mongolia, China, Russia, Central Asia, Pakistan, Turkey, Africa, and South America, with an HDV prevalence as high as 60% being reported in HBV-infected patients in Mongolia and Pakistan.

About Eiger

Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of Orphan diseases.  The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed.

Safe Harbor Statements

Additional Information about the Proposed Merger between Celladon Corporation and Eiger BioPharmaceuticals, Inc. and Where to Find It

In connection with the proposed merger between Celladon Corporation and Eiger BioPharmaceuticals, Inc., Celladon has filed a registration statement on Form S-4 with the Securities and Exchange Commission, or the SEC, including a proxy statement/prospectus/information statement, but the registration statement has not yet become effective.   The proxy statement/prospectus/information statement and any other relevant documents filed by Celladon with the SEC may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Celladon by directing a written request to: Celladon Corporation, 12707 High Bluff Dr #200, San Diego, CA 92130, Attention: Investor Relations.  Investors and security holders are urged to read the proxy statement/prospectus/information statement and the other relevant materials before making any voting or investment decision with respect to the proposed merger.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Celladon and its directors and executive officers and Eiger and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Celladon in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the merger is included in the proxy statement/prospectus/information statement referred to above. Additional information regarding the directors and executive officers of Celladon is also included in Celladon Annual Report on Form 10-K for the year ended December 31, 2014 and the proxy statement for Celladon’s 2015 Annual Meeting of Stockholders. These documents are available free of charge at the SEC web site (www.sec.gov) and from Investor Relations at Celladon at the address described above.

Investors: Jim Shaffer, Eiger Bio, Inc., 919-345-4256, jshaffer@eigerbio.com

Logo – http://photos.prnewswire.com/prnh/20151108/285009LOGO

SOURCE Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals kündigt die erste Behandlung von Patienten in der Phase-II LOWR HDV – 4 (LOnafarnib mit Ritonavir bei Hepatitis Delta Virus – 4) Studie an der Medizinischen Hochschule Hannover, in Hannover, Deutschland, an

January 6, 2016 – 6:00 am

PALO ALTO, Kalifornien, 6. Januar 2016 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. kündigte heute den Beginn der Rekrutierung und die erste Behandlung von Patienten in LOWR HDV – 4 (LOnafarnib With Ritonavir bei Hepatitis Delta Virus – 4) an der Medizinischen Hochschule Hannover, in Hannover, Deutschland, an. LOWR HDV – 4 ist eine Open Label Dosis-Titrationsstudie, die zur Evaluierung der Wirksamkeit und Verträglichkeit von Lonafarnib in Kombination mit Ritonavir für insgesamt 24 Wochen in fünfzehn Patienten mit chronischer Hepatitis Delta ausgelegt ist.

Logo – http://photos.prnewswire.com/prnh/20151108/285009LOGO

„Wir freuen uns über die Teilnahme an der Phase-II-Studie mit Lonafarnib in Patienten mit Hepatitis Delta-Infektionen”, sagte Dr. Heiner Wedemeyer, leitender Studienarzt, Leiter der Forschungsgruppe der Klinik für Gastroenterologie, Hepatologie und Endokrinologie an der Medizinischen Hochschule Hannover und Gründungsmitglied von Hepatitis Delta International Network (HDIN). „Wir haben uns der Weiterentwicklung der Forschung und Identifizierung effektiver therapeutischer Optionen für Patienten mit HDV Infektionen verpflichtet, der aggressivsten Form der chronischen Virushepatitis.”

„Dr. Wedemeyer ist bereits seit Langem Berater von Eiger BioPharmaceuticals und wir sind stolz, dass wir die Medizinische Hochschule Hannover in die Entwicklung von Lonafarnib bei HDV einbinden können”, sagte DDr. Eduardo Martins, Senior Vice President of Liver and Infectious Diseases Drug Development von Eiger BioPharmaceuticals. „LOWR HDV – 4 ist dazu ausgelegt, die potenziellen Vorteile von Dosis-Titration sowie das antivirale Potenzial von Lonafarnib in Kombination mit Ritonavir in einer länger dauernden Studie aufzuklären.”

Über Sarasar® (Lonafarnib)

Lonafarnib ist ein gut beschriebener, nahezu marktreifer, oral aktiver Farnesyltransferaseinhibitor, ein Enzym, das an der Modifizierung von Proteinen in einem als Prenylierung bezeichneten Prozess beteiligt ist. HDV nutzt diesen Wirtszellenprozess in Leberzellen, um einen wichtigen Schritt in seinem Lebenszyklus zu vollziehen. Lonafarnib unterdrückt den Prenylierungsschritt der HDV-Replikation in den Leberzellen und blockiert den Lebenszyklus des Virus in der Phase der Assemblierung. Da die Prenylierung durch ein Wirtsenzym erfolgt, könnte dieser Wirkstoff eine höhere Barriere für die Entwicklung viraler Resistenzmutationen darstellen. Lonafarnib wurde in internationalen akademischen Zentren an über 50, mit HDV infizierte Patienten verabreicht und befindet sich in der Phase-II-Entwicklung bei HDV. Lonafarnib erhielt in den USA von der FDA und von der Europäischen Arzneimittelagentur (EMA) den Orphan Drug-Status, und in den USA den Fast Track-Status von der FDA. Lonafarnib ist für keine Indikation zugelassen und wurde von Merck Sharp & Dohme Corp. (außerhalb der Vereinigten Staaten und Kanada als MSD bekannt) lizenziert.

Über das Hepatitis Delta Virus (HDV)

Hepatitis Delta (oder Hepatitis D) wird durch eine Infektion mit dem HDV hervorgerufen und gilt als die schwerste Form der viralen Hepatitis beim Menschen. Hepatitis D tritt nur als Koinfektion bei Personen mit Hepatitis B (HBV) auf. Hepatitis D führt zu einer schwereren Lebererkrankung als HBV alleine und steht im Zusammenhang mit beschleunigter Leberfibrose, Leberkrebs und Leberversagen. Hepatitis D ist eine Krankheit mit erheblicher Auswirkung auf die Weltgesundheit und betrifft etwa 15 Millionen Menschen weltweit. Die Verbreitung von HDV ist in verschiedenen Teilen der Welt unterschiedlich. Weltweit wird von HDV-Infektionen bei etwa 5 ‑ 6 % der chronischen Hepatitis B-Träger ausgegangen. In einigen Teilen der Welt, einschließlich bestimmter Gebiete der Mongolei, Chinas, Russlands, Zentralasiens, Pakistans, der Türkei, Afrikas und Südamerikas, ist die Prävalenz von HDV in Patienten mit chronischem HBV sogar noch höher und in der Mongolei und in Pakistan wird von einer Verbreitung von bis zu 60 % bei den mit HBV infizierten Patienten berichtet.

Über Eiger

Eiger ist ein auf der klinischen Stufe aktives Biopharmaunternehmen, dessen Ziel es ist, neuartige Produkte zur Behandlung seltener Erkrankungen auf den Markt zu bringen. Das Unternehmen verfügt über ein breites Portfolio von gut definierten Produktkandidaten, die das Potenzial zur Behandlung von Erkrankungen mit hohem ungedecktem medizinischen Bedarf besitzen, bei denen die Biologie der Behandlung geklärt ist und eine effektive Therapie dringend benötigt wird.

Safe Harbor-Erklärungen

Zusätzliche Informationen über die vorgeschlagene Fusion von Celladon Corporation und Eiger BioPharmaceuticals, Inc., und wo Sie sie finden können

In Zusammenhang mit der vorgeschlagenen Fusion zwischen Celladon Corporation und Eiger BioPharmaceuticals, Inc., hat Celladon bei der Securities and Exchange Commission, der SEC, ein Registration Statement auf Formular S-4 eingereicht, einschließlich einer Stimmrechtsvollmacht, eines Prospekts und eines Informationsblattes, allerdings ist das Registration Statement noch nicht in Kraft. Die Stimmrechtsvollmacht, der Prospekt und das Informationsblatt sowie sämtliche anderen, von Celladon bei der SEC eingereichten Dokumente stehen kostenlos auf der Website der SEC unter www.sec.gov zur Verfügung. Zusätzlich können Investoren und Inhaber von Wertpapieren kostenlose Kopien der bei der SEC eingereichten Dokumente schriftlich unter nachstehender Adresse anfordern: Celladon Corporation, 12707 High Bluff Dr #200, San Diego, CA 92130, zu Händen: Investorenbeziehungen. Investoren und Inhabern von Wertpapieren wird empfohlen, die Stimmrechtsvollmacht, den Prospekt und das Informationsblatt sowie die anderen, relevanten Unterlagen zu lesen, bevor sie eine Entscheidung über die Stimmabgabe oder Investitionen in Zusammenhang mit der vorgeschlagenen Fusion treffen.

Diese Mitteilung stellt kein Angebot zum Verkauf oder eine Aufforderung zur Abgabe eines Verkaufsangebotes oder eine Aufforderung zur Abgabe eines Kaufangebotes für irgendwelche Wertpapiere dar, noch wird in irgendeiner Gerichtsbarkeit ein Verkauf von Wertpapieren erfolgen, in der ein derartiges Angebot, eine Aufforderung oder der Verkauf vor der Registrierung oder Qualifikation nach den Wertpapiergesetzen einer solchen Gerichtsbarkeit unzulässig ist. Wertpapiere in Zusammenhang mit der vorgeschlagenen Fusion werden ausschließlich auf Grundlage eines Prospekts angeboten, der den Erfordernissen der Section 10 des Securities Act von 1933 in seiner jeweils geltenden Fassung entspricht.

Celladon, seine Direktoren und Führungskräfte, und Eiger, seine Direktoren und Führungskräfte sind als Beteiligte an der Werbung von Stimmrechtsvollmachten von Aktionären von Celladon in Zusammenhang mit der vorgeschlagenen Transaktion anzusehen. Informationen über die besonderen Interessen dieser Direktoren und Führungskräfte in Zusammenhang mit der Fusion sind in der vorstehend genannten Stimmrechtsvollmacht, dem Prospekt und dem Informationsblatt enthalten. Zusätzliche Informationen über die Direktoren und Führungskräfte von Celladon finden Sie ebenfalls im Jahresbericht für das am 31. Dezember 2014 endende Jahr auf Formular 10-K und in den Stimmrechtsvollmachten für die Jahreshauptversammlung 2015 von Celladon. Diese Dokumente stehen kostenlos auf der Website der SEC (www.sec.gov) und bei Investorenbeziehungen von Celladon unter der vorstehend genannten Adresse zur Verfügung.

Investoren: Jim Shaffer, Eiger Bio, Inc., 919-345-4256, jshaffer@eigerbio.com

Abide Therapeutics Appoints Dr. Chan Beals As Chief Medical Officer

January 6, 2016 – 6:00 am

SAN DIEGO, Jan. 6, 2016 /PRNewswire/ — Abide Therapeutics announced today the appointment of Chan Beals, M.D., Ph.D., to the position of Chief Medical Officer. Dr. Beals has more than 15 years of experience in the pharmaceutical industry, with extensive expertise in both early and late stage clinical development.

Dr. Beals was most recently Entrepreneur in Residence with Merck Research Laboratories Ventures, a vehicle by which Merck interacts with nascent biotechnology companies.  Dr. Beals was involved with all facets of search and evaluation, deal terms, building internal consensus for investments, and monitoring their progress.  Prior to his role at Merck Research Laboratory Ventures, Dr. Beals was Vice President and Head of Clinical Pharmacology and Experimental Therapeutics at Merck & Co, where he was responsible for overseeing preclinical and clinical development of new therapeutics. During that time, Dr. Beals led the introduction of 30 molecules into early clinical development of which 11 molecules entered late stage clinical development.  

“Dr. Chan Beals has an exceptional background to ensure that Abide continues to build and execute on translating exciting molecules from our maturing pipeline into small proof of biology clinical studies that will guide the choices for further development.  Dr. Beals’ task is enabled by the fact that the Abide platform, by its design, yields translational biomarkers for each program,” said Alan Ezekowitz, MBChB, D.Phil., President and CEO of Abide Therapeutics. “With our first clinical study launched, the time is ideal to bring Dr. Beals aboard as we expand this program and advance our follow on first-in-class therapeutics.”

In July 2015, Abide began enrollment in its first clinical study, a Phase 1a clinical study of ABX-1431, an investigational endocannabinoid system modulator with potential indications in symptomatic improvement in multiple sclerosis, neuroinflammation, acute and chronic pain, agitation in Alzheimer’s Disease and pain in irritable bowel syndrome.

“I look forward to joining the team at Abide Therapeutics, who are working with an exciting and relatively unexplored class of therapeutics,” said Dr. Beals. “Abide has a tremendous opportunity to build out a pipeline of novel drugs that have the potential to fight a wide range of disorders from neurological to infectious diseases.”

Dr. Beals earned his M.D. and a Ph.D. in biochemistry from the University of Washington School of Medicine and his B.S. in chemistry from the Massachusetts Institute of Technology. He completed a residency in pediatrics and fellowship in pediatric rheumatology at the University of California, San Francisco.

About Serine Hydrolases 
The large family of serine hydrolases are validated but largely underexplored as drug targets. These enzymes play a key regulatory role in human physiological processes, such as regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, and life cycle of viruses and pathogens. Thus, the ability to target serine hydrolases has broad therapeutic applications. The proprietary Abide technology platform provides a unique highly selective small molecule collection that specifically targets the common catalytic site of serine hydrolases. The technology provides a rapid and effective method for target identification and validation. 

About Abide Therapeutics 
Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Serine hydrolases play important regulatory roles in human physiology and disease. Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger, that specifically targets serine hydrolases with selective small molecules. The ability to target and modulate serine hydrolases has potential to develop new medicines in many therapeutic areas. Abide is located in San Diego. To learn more, visit www.abidetx.com

 

SOURCE Abide Therapeutics

ImaginAb’s PSMA Imaging Agent Detects More Lesions Compared to Standard Imaging Methods for Detection of Prostate Cancer in Phase I/IIa Study

January 6, 2016 – 6:00 am

LOS ANGELES, Jan. 6, 2016 /PRNewswire/ — ImaginAb Inc. today announced clinical results from a Phase I/IIa trial of IAB2M, ImaginAb’s proprietary precision imaging agent for the detection of metastatic prostate cancer. In the study, IAB2M was able to detect bone lesions and soft-tissue lesions with far greater specificity and sensitivity than standard imaging methods. The study was conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK), with results being presented on Jan. 7 at the 2016 Genitourinary (GU) Cancers Symposium in San Francisco.

“There’s a pressing need for improved imaging biomarkers to identify disease distribution and treatment response in both localized and advanced prostate cancer patients,” said Michael J. Morris, M.D., of Memorial Sloan Kettering Cancer Center and investigator in the study. “IAB2M’s high concordance with pathology results provides evidence that positive imaging results represent prostate cancer.”

IAB2M is a radiolabeled monoclonal antibody fragment targeting prostate-specific membrane antigen (PSMA), a transmembrane protein that is highly expressed in prostate cancer. The technology is being developed as a diagnostic imaging agent for use with positron emission tomography (PET) to accurately stage men diagnosed with prostate cancer.

The Phase I/IIa study included 38 patients with progressive metastatic prostate cancer. All patients underwent standard imaging using CT, bone scintigraphy (BS) and FDG PET, followed by imaging with IAB2M. Whole body PET/CT scans were performed. Researchers evaluated the lesion targeting and uptake of IAB2M and correlation with pathology of biopsied lesions.

In bone, IAB2M detected 344 lesions (83.9%), CT 209 (51%), BS 211 (51.5%), and FDG 109 (26.6%). For soft tissue, IAB2M detected 119 (81.5%), CT 83 (56.8%), and FDG 79 (54.1%). Of 27 evaluable biopsies, 20/27 (74.1%) were positive for prostate cancer; 20/24 (83.3%) IAB2M positive lesions were pathology positive; and 3/3 (100%) IAB2M negative lesions were negative on pathology. All imaging and pathology correlated (true pos + true neg) in 23/27 (85.2%) biopsies.

“These data provide important clinical proof of concept demonstrating how our technology can detect more lesions than standard imaging,” said Benjamin Chen, Chief Executive Officer of ImaginAb. “IAB2M provides a way for physicians to physically see the location and extent of diseased tissue, and holds promise as an important tool to make treatment decisions.”

The study, “A phase I/IIa trial of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa),” is available on the 2016 GU Cancers Symposium website at http://abstracts.asco.org.

After skin cancer, prostate cancer is the most common cancer among men. About 1 man in 7 will be diagnosed with prostate cancer during his lifetime. ImaginAb’s IAB2M imaging agent can improve diagnostic intelligence and may impact the clinical development of therapeutics, particularly in the anti-androgen space, as existing measures of radiographic progression are insensitive and biased toward late-stage disease. 

About ImaginAb 
ImaginAb Inc. is an immune imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling truly personalized medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also advancing a best-in-class imaging agent to improve prostate cancer management and patient outcomes. ImaginAb’s products have the potential to improve patient care and lower healthcare costs. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.

Media Contact:
Jason Spark
Canale Communications for ImaginAb Inc.
1-619-849-6005
jason@canalecomm.com 

 

SOURCE ImaginAb Inc.

ImaginAb’s PSMA Imaging Agent Detects More Lesions Compared to Standard Imaging Methods for Detection of Prostate Cancer in Phase I/IIa Study

January 6, 2016 – 6:00 am

LOS ANGELES, Jan. 6, 2016 /PRNewswire/ — ImaginAb Inc. today announced clinical results from a Phase I/IIa trial of IAB2M, ImaginAb’s proprietary precision imaging agent for the detection of metastatic prostate cancer. In the study, IAB2M was able to detect bone lesions and soft-tissue lesions with far greater specificity and sensitivity than standard imaging methods. The study was conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK), with results being presented on Jan. 7 at the 2016 Genitourinary (GU) Cancers Symposium in San Francisco.

“There’s a pressing need for improved imaging biomarkers to identify disease distribution and treatment response in both localized and advanced prostate cancer patients,” said Michael J. Morris, M.D., of Memorial Sloan Kettering Cancer Center and investigator in the study. “IAB2M’s high concordance with pathology results provides evidence that positive imaging results represent prostate cancer.”

IAB2M is a radiolabeled monoclonal antibody fragment targeting prostate-specific membrane antigen (PSMA), a transmembrane protein that is highly expressed in prostate cancer. The technology is being developed as a diagnostic imaging agent for use with positron emission tomography (PET) to accurately stage men diagnosed with prostate cancer.

The Phase I/IIa study included 38 patients with progressive metastatic prostate cancer. All patients underwent standard imaging using CT, bone scintigraphy (BS) and FDG PET, followed by imaging with IAB2M. Whole body PET/CT scans were performed. Researchers evaluated the lesion targeting and uptake of IAB2M and correlation with pathology of biopsied lesions.

In bone, IAB2M detected 344 lesions (83.9%), CT 209 (51%), BS 211 (51.5%), and FDG 109 (26.6%). For soft tissue, IAB2M detected 119 (81.5%), CT 83 (56.8%), and FDG 79 (54.1%). Of 27 evaluable biopsies, 20/27 (74.1%) were positive for prostate cancer; 20/24 (83.3%) IAB2M positive lesions were pathology positive; and 3/3 (100%) IAB2M negative lesions were negative on pathology. All imaging and pathology correlated (true pos + true neg) in 23/27 (85.2%) biopsies.

“These data provide important clinical proof of concept demonstrating how our technology can detect more lesions than standard imaging,” said Benjamin Chen, Chief Executive Officer of ImaginAb. “IAB2M provides a way for physicians to physically see the location and extent of diseased tissue, and holds promise as an important tool to make treatment decisions.”

The study, “A phase I/IIa trial of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa),” is available on the 2016 GU Cancers Symposium website at http://abstracts.asco.org.

After skin cancer, prostate cancer is the most common cancer among men. About 1 man in 7 will be diagnosed with prostate cancer during his lifetime. ImaginAb’s IAB2M imaging agent can improve diagnostic intelligence and may impact the clinical development of therapeutics, particularly in the anti-androgen space, as existing measures of radiographic progression are insensitive and biased toward late-stage disease. 

About ImaginAb 
ImaginAb Inc. is an immune imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling truly personalized medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also advancing a best-in-class imaging agent to improve prostate cancer management and patient outcomes. ImaginAb’s products have the potential to improve patient care and lower healthcare costs. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.

Media Contact:
Jason Spark
Canale Communications for ImaginAb Inc.
1-619-849-6005
jason@canalecomm.com 

 

SOURCE ImaginAb Inc.